Discovery of a dual inhibitor of NQO1 and GSTP1 for treating glioblastoma

Abstract

Thus, MNPC, a dual inhibitor for both NQO1 and GSTP1, provides a novel lead compound for treating GBM via the exploitation of specific vulnerabilities created by mutant EGFR.